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Abstract
The number of obese patients has increased annually worldwide. Therefore, there is a strong need to develop a
new effective and safe anti-obesity drug. Miglitol is an alpha-glucosidase inhibitor (αGI) that is commonly used as
an anti-diabetic drug, and there is growing evidence that it also has anti-obesity effects. Miglitol has been shown
to reduce body weight and ameliorate insulin resistance in both clinical trials with adult patients and in rodent
models of obesity. Although the specific mechanism of action of this effect remains unclear, some mechanisms
have been suggested through experimental results. Miglitol has been shown to inhibit adipogenesis of white
adipocytes in vitro, activate brown adipose tissue (BAT) in mice, influence bile acid metabolism in mice, and
regulate the secretion of incretin hormones in humans. Among these results, we consider that BAT activation is
likely the definitive mediator of miglitol’s anti-obesity effect. A unique advantage of miglitol is that it is already
used as an anti-diabetic drug with no severe side effects, whereas many of the anti-obesity drugs developed to
date have been withdrawn because of their severe side effects. Miglitol is currently used clinically in a limited
number of countries. In this review, we provide an overview of the state of research on miglitol for obesity
treatment, emphasizing that it warrants more detailed attention. Overall, we demonstrate that miglitol shows
good potential as a therapeutic for the treatment of obesity. Thus, we believe that further investigations of how
it exerts its anti-obesity effect will likely contribute to the development of a new class of safe and effective drugs
against obesity.
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Background
Obesity is a worldwide health problem that causes vari-
ous diseases such as diabetes, cardiovascular disease,
stroke, and cancer. Many pharmaceutical companies
have invested substantial capital and labor to develop
anti-obesity drugs; however, most of the anti-obesity
drugs that have thus far been approved and marketed
have ultimately been withdrawn because of their serious
adverse effects (e.g., psychological symptoms, increased
risk of heart attack and stroke, and sudden death) [1, 2].
Miglitol is commonly prescribed to diabetic patients, as
it reduces postprandial hyperglycemia by inhibiting
alpha-glucosidase in the small intestine, and thereby
prolongs carbohydrate absorption [3]. Miglitol was
approved as an anti-diabetic drug in 1996 and has since
been sold in Japan, the USA, Australia, France,
Germany, Spain, Switzerland, and Mexico. Furthermore,
there is growing evidence that miglitol also exerts an
anti-obesity effect based on both animal and human
studies. This review summarizes the basic and clinical
research conducted to date on the anti-obesity effect of
miglitol. We first provide an overview of recent and
current clinical trials conducted for miglitol, given that
the drug has long been used in a clinical setting for dia-
betes, and thus its effects on patients and potential anti-
obesity potential were first observed in a clinical context.
These observations and trials have motivated basic re-
search studies conducted in vitro and with animal
models to elucidate the underlying mechanisms of migli-
tol’s observed clinical effects. These studies are therefore
described in the latter part of the review, demonstrating
what is known and what remains to be discovered. Fi-
nally, we discuss the future directions of miglitol and its
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unique advantages for translation from an anti-diabetic
to an anti-obesity drug, and compare its effects and po-
tential to other currently Food and Drug Administration
(FDA)-approved anti-obesity drugs. Collectively, this
review highlights the need for further basic research as
well as clinical studies in countries other than Japan,
especially those with a high incidence of obesity.
Clinical trials for miglitol’s anti-obesity effect
There have been four clinical trials (randomized open-
label studies) reported to date, which have all been carried
out in Japan, clearly demonstrating that miglitol shows an
anti-obesity effect [4–7] (Table 1). In all four studies,
miglitol significantly reduced the body weight and
body mass index of obese or type 2 diabetic patients.
Shimabukuro et al. [4] enrolled the largest number of
patients (n = 111), which were divided into a life-style
modification (LSM)-only group and an LSM-plus-
miglitol treatment group. They demonstrated that miglitol
lowered homeostatic model assessment-insulin resistance
(HOMA-R) and decreased insulin levels during the oral
glucose tolerance test, which suggested that miglitol could
ameliorate insulin resistance. Subcutaneous/visceral fat
mass and systolic/diastolic blood pressure were decreased
in the LSM-plus-miglitol group. Furthermore, miglitol
improved total cholesterol (T-Cho), low-density lipopro-
tein (LDL)-cholesterol, γ-glutamyl transpeptidase, high-
sensitive C-reactive protein, and adiponectin in the blood.
Mikada et al. [6] demonstrated that miglitol reduced total
body fat mass and lowered systolic blood pressure.
Furthermore, Narita et al. [5] and Sugihara et al. [7] dem-
onstrated that miglitol was more effective than other
alpha-glucosidase inhibitors (αGIs; e.g., voglibose or acar-
bose) at reducing body weight gain. No severe side effects
were observed in any of these studies. There is further evi-
dence that miglitol could reduce appetite and food intake
in humans [8, 9], thus supporting its anti-obesity effect,
although the evaluations in these studies were of a very
short duration and were somewhat limited to derive a
conclusive result.
These four clinical trials conducted in Japan strongly
suggest that miglitol exerts an anti-obesity effect in
humans. Nevertheless, higher quality clinical research
should be performed before miglitol can be conclusively
demonstrated to reduce obesity in humans. Further-
more, these previous studies involved a small number of
only Japanese patients; therefore, future studies should
enroll a larger number of patients, and the studies
should be carried out for a longer duration in a non-
blinded manner. The studies should also be performed
in countries that have a high rate of obesity.
Two of the four clinical trials described above tried to
verify the mechanism by which miglitol reduces obesity
[5, 6]. Narita et al. [5] and Mikada et al. [6] focused on
the role of incretin hormones. Incretin hormones are se-
creted from the gastrointestinal tract in response to meals,
and contribute to the regulation of glucose homeostasis
by stimulating insulin secretion from the pancreas in a
glucose-dependent manner [10]. Incretin hormones also
have extra-pancreatic effects, including an anti-obesity ef-
fect. Glucose-dependent insulinotropic peptide (GIP) and
glucagon-like peptide 1 (GLP1) are the two main incretin
hormones. GIP promotes fat accumulation [11], whereas
GLP1 reduces appetite and food intake [12–14]. These
findings suggest that a strategy aimed at enhancement of
GLP1 signals or suppression of GIP1 signals has potential
to alleviate obesity. Narita et al. [5] demonstrated that
miglitol decreased plasma GIP levels and increased plasma
GLP1 levels. Specifically, they found that body weight
change was correlated with GIP but not GLP1, leading to
the speculation that suppression of GIP secretion is the
main contributor to the observed body weight reduction.
Mikada et al. [6] also demonstrated that miglitol decreased
plasma GIP levels and increased plasma GLP1 levels; how-
ever, it was not clear whether the change in GIP and
GLP1 levels was associated with the degree of obesity.
Basic research of miglitol’s anti-obesity effect and
potential mechanisms
There have been five basic research reports including
ours [15] demonstrating that miglitol reduces obesity in
rodents [16–19]. Furthermore, in support of the results
of the clinical studies indicated above with respect to the
role of incretin hormones, we measured the blood con-
centrations of GIP and GLP1 in mice treated with and
without miglitol under a high-fat diet, and found no sig-
nificant difference between the groups (Table 2) [15].
Hamada et al. [17] and Sasaki et al. [18] demonstrated
that the blood concentration of GLP1 was significantly
higher in the miglitol-treated group than in the untreated
group fed a high-fat diet. However, because there was no
difference in food intake between the miglitol-treated and
untreated groups, it appears that GLP1 did not directly
contribute to obesity reduction in these studies. There-
fore, despite several lines of evidence demonstrating
that miglitol regulates incretin hormones, there is no
conclusive evidence that this regulation contributes to
obesity reduction.
The first study on the effects of miglitol in an animal
model was reported by Debouno et al. in 1993 [16].
They used SHR/Ntul-cp rats as a model, which show a
tendency toward early-onset obesity and non-insulin
dependent diabetes mellitus. In this study, miglitol was
found to reduce body weight gain without affecting food
intake. The other four studies also demonstrated that
miglitol reduced body weight gain with no difference of
food intake in obese rodent models [15, 17–19]. Our
group and Sasaki et al. demonstrated that the reduction
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Study participants Comparison Change of BW (kg)
Mean ± SD
Results Side effects






Men and women aged
34–69 years with metabolic
syndrome
Lifestyle modification
(LSF) (n = 56) vs LSF
with miglitol (n = 55)
Before/After treatment:
72.6 ± 11.7/68.9 ± 10.4
Parameters improved in LSF +miglitol:
BW, systolic and diastolic blood pressure,
HOMA-R, blood examination (T-cho, LDL,
TG, γGTP, high sensitive CRP, HbA1c,
1,5-AG), insulin and blood glucose during
OGTT, SFA , mean % change from baseline
in VFA.










50 patients with type 2 DM
with diet therapy alone or
with oral hypoglycemic
agents other than αGI
Miglitol (n = 26) vs
voglibose (n = 24)
64.5 ± 14.0/63.6 ± 14.0 Parameters improved in miglitol group:
BW, BMI
Parameters improved in both groups:
HbA1c, 2-hour MTT (plasma glucose AUC,
insulin AUC)
Both miglitol and voglibose decreased
total GIP and increased active GLP1 during
the MTT (GIP was lower in the miglitol
group than in the voglibose group).
Not documented





41 patients with type 2 DM
and overweight (BMI≥ 25)
aged 20–80 years
Miglitol (n = 14) vs
sitagliptin (n = 14) vs
both drugs (n = 13)
81.4 ± 11.2/79.9 ± 11.5 (Data are shown for only the miglitol-
treated group): BW, BMI, total body fat
mass, systolic blood pressure, blood
glucose-iAUC, and insulin-iAUC decreased
after treatment compared with before
treatment. Miglitol decreased total GIP-
iAUC and increased total GLP1-iAUC, but
did not affect active GIP-iAUC and active
GLP1-iAUC.
Not documented




81 patients with obesity
and type 2 diabetes
(BMI≥ 25) aged ≥40 years
Control (n = 22),
miglitol (n = 18),
acarbose (n = 22),
voglibose (n = 19)
69.0 ± 11.2/67.8 ± 11.2 In only the miglitol group BW and BMI
decreased after treatment compared with
before treatment at 4, 8, and 12 weeks.
HbA1c decreased after treatment compared
with before treatment in the control (at 12
weeks) and in the miglitol-treated group
(at 4, 8, and 12 weeks).
Some digestive
symptoms observed
in the three αGI-treated
groups
Abbreviations: DM diabetes mellitus, BW body weight, HOMA-R homeostatic model assessment-insulin resistance, T-Cho total cholesterol, LDL low-density lipoprotein, TG triglycerides, CRP C-reactive protein, HbA1c
hemoglobin A1c, 1,5-AG 1,5-anhydroglucitol, OGTT oral glucose tolerance test, SFA subcutaneous fat area, VFA visceral fat area, BMI body mass index, MTT meal tolerance test, AUC area under the curve, GIP glucose-














of body weight was accompanied by a reduction in
epididymal white adipose tissue (WAT) in high-fat diet-
induced obese mice (Table 2) [15, 18]. Miglitol also
reduced subcutaneous WAT weight in our experiment
[15]. In addition, similar to Hamada et al. [17], we fur-
ther demonstrated that miglitol reduced HOMA-R
(Table 2) [15]. Hamada et al. [17] also found that migli-
tol decreased blood glucose and insulin levels during an
oral glucose tolerance test, and reduced blood glucose
during the insulin tolerance test, which suggest that
miglitol ameliorates insulin resistance, glucose tolerance,
and insulin sensitivity in a spontaneous-onset obesity
type 2 diabetic mouse model. Shrivastava et al. [19] dem-
onstrated that miglitol improved the plasma lipid profile
levels, including T-Cho, triglycerides (TG), phospho-
lipids, free fatty acids, LDL, and very low-density lipo-
protein, in high-fat diet-fed rats, and decreased plasma
levels of T-cho and TG in hyperlipidemic rats. Based on
these reports it is clear that miglitol has an anti-obesity
effect in rodents as well as in humans. Sasaki et al. [18]
demonstrated that there was no effect of miglitol on
locomotor activity, which suggested that an increase in
exercise did not mediate the anti-obesity effect induced
by miglitol. Common adverse effects of miglitol, such as
abdominal distension, diarrhea, or anorexia, were not
observed in neither our study [15], the Sasaki et al. [18]
study, nor the Debouno et al. [16] study (the other two
reports did not refer to side effects.). These findings
suggest that suppression of energy intake does not con-
tribute to miglitol’s anti-obesity effect.
Although the first study by Debouno et al. did not
verify the mechanism by which miglitol reduces obes-
ity, the other four reports attempted to elucidate the
mechanism [15, 17–19]. In particular, miglitol appears
to mediate weight reduction via its effects on brown
adipose tissue (BAT) and, potentially, white adipo-
cytes. Two mechanisms have been proposed for the
former effect, whereas one mechanism has been pro-
posed for the latter effect.
Miglitol reduces obesity via activating BAT
Three of the four reports [15, 17, 18] suggested that
BAT is involved in miglitol’s anti-obesity effect. BAT is
generally considered to disappear after infancy. However,
recent studies using positron emission tomography/
computed tomography have shown that adult humans
retain metabolically active BAT. BAT dissipates energy
as heat and contributes to enhancement of energy ex-
penditure, and is thus an important target of obesity
treatment [20–22]. UCP1 is a key molecular for BAT
thermogenesis. UCP1 uncouples adenosine-5′-triphos-
phate (ATP) synthesis from substrate oxidation in brown
adipocytes. When UCP1 is activated, protons freely flow
across the inner mitochondrial membrane, which results
in the rapid dissipation of chemical energy as heat. The
upregulation of UCP1 induces increased energy expend-
iture, which contributes to the prevention or reduction
of obesity [23]. Recently, our group as well as Sasaki
et al. clearly showed that miglitol’s anti-obesity effect
was attributed to increased energy expenditure by upreg-
ulating UCP1 expression of BAT in mice [15, 18]. Con-
sistent with upregulation of UCP1, miglitol increased
oxygen consumption, which is an index of basal metab-
olism, and promoted heat generation of interscapular
BAT in our experiment [15]. Although differences were
observed with respect to the age of mice and the dosage
of miglitol administered, Sasaki et al. [18] demonstrated
that miglitol increased oxygen consumption in mice.
Furthermore, we and Sasaki et al. demonstrated that the
upregulation of UCP1 is attributed to enhancement of
β-adrenergic signaling [15, 18]. Hamada et al. [17] also
suggested that BAT might be one of miglitol’s targets, al-
though they proposed a different mechanism, in which
miglitol modifies BA metabolism.
Proposed mechanism I: Miglitol enters the circulation and
directly enhances the β3-aderenergic signaling of BAT
β3-adrenergic signaling enhances UCP1 expression
through β3-adrenergic receptor (β3AR) and thus plays a
Table 2 Metabolic parameters in 8-week-old mice (Based on Sugimoto et al. [15].)
n NC NCM HF HFM
Body weight (g) 10–11 21.5 ± 0.2 22.2 ± 0.2 27.3 ± 0.4 *, ** 25.8 ± 0.4 *, **, ***
HOMA-R 5 1.4 ± 0.3 1.1 ± 0.3 8.4 ± 1.3 *, ** 4.0 ± 0.7 *, **, ***
Weight of epididymal white adipose tissue (g) 9–14 0.27 ± 0.02 0.28 ± 0.01 1.1 ± 0.08 *, ** 0.85 ± 0.04 *, **, ***
Weight of subcutaneous white adipose tissue (g) 6 0.3 ± 0.03 Not measured 1.5 ± 0.15 * 0.98 ± 0.12 *, ***
Active glucose-dependent insulinotropic peptide (GIP) (pg/mL) 9–15 28.2 ± 3.6 20.4 ± 2.5 38.8 ± 4.7 ** 32.0 ± 4.3
Active glucagon-like peptide 1 (GLP1) (pg/mL) 8–9 54.8 ± 7.9 61.1 ± 4.9 66 ± 7.5 76.9 ± 14.4
Concentration of miglitol (μmol/L) 3–4 Not measured 0.06 ± 0.02 Not Measured 0.26 ± 0.13
*p < 0.05 vs NC; **p < 0.05 vs NCM; ***p < 0.05 vs HF
Values are means ± SE for 3–15 mice. Four-week-old male C57BL/6 J mice were divided into 4 groups: a control group (NC), which was fed normal chow; a normal
chow plus miglitol (NCM) group, which was fed the normal chow plus miglitol; a high fat (HF) group, which was fed the high fat diet; and a high fat plus miglitol
(HFM) group, which was fed the high fat diet plus miglitol. At 8 weeks the samples were collected under fasting conditions. Repeated-measures analysis of variance
(ANOVA) with Tukey-Kramer post-hoc comparisons were performed for multiple comparisons
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role in alleviating obesity [23]. Stimulation of β3AR induces
increased cyclic AMP (cAMP) generation and subsequent
activation of protein kinase A (PKA). Hormone-sensitive
lipase (HSL), p38 α-mitogen-activated protein kinase
(p38αMAPK), and peroxisome proliferator-activated re-
ceptor gamma coactivator 1α (PGC1α) are downstream
molecules of PKA [15, 24]. Activating transcription factor
2 (ATF2) and cAMP response element binding protein
(CREB) bind to the PGC1α promoter and enhance its
transcription [25].
We clarified that miglitol increased the mRNA and
protein expression of UCP1 and the expression of the
four proteins involved in the signaling cascade (PKA,
HSL, p38αMAPK, and PGC1α) in high-fat diet-induced
obese mice. Miglitol increased the amount of cAMP and
phosphorylated PKA (pPKA) protein levels in the pres-
ence of a β3AR agonist in our experiment, which con-
firmed that miglitol enhances β3-aderenergic signaling
[15]. Sasaki et al. [18] investigated the direct effect of
miglitol on brown adipocytes using HB2 cells (differenti-
ated immortalized brown preadipocytes). Miglitol in-
creased the amount of cAMP and the phosphorylation
of CREB and ATF2 under βAR agonist (isoproterenol)
stimulation, which further suggests that miglitol directly
enhances β-aderenergic signaling. Miglitol was reported
to transfer into the blood circulation, unlike other αGIs
[26, 27]; indeed, miglitol was detected in the blood in
our study (Table 2). Sasaki et al. [18] also showed that
intraperitoneal injection of miglitol increased oxygen
consumption in mice, which suggests that circulation of
miglitol directly activates BAT. Both our study and the
Sasaki et al. study [15, 18] suggest that miglitol enters
the blood circulation where it directly activates BAT in
mice (Fig. 1). Anti-obesity drugs that act on the central
nervous system and reduce food intake tend to cause
psychological side effects [1, 28]. Therefore, the finding
that miglitol directly acts on peripheral tissues (such as
BAT) suggests a new and fascinating mechanism for
obesity inhibition [18].
Proposed mechanism II: Miglitol activates BAT via bile acid
(BA)
BA was reported to stimulate the G protein-coupled
receptor of BAT (TGR5) and increase energy expend-
iture by activating type 2 iodothyronine deiodinase
(DIO2) [29], a cyclic AMP-dependent thyroid hormone-
activating enzyme. The BA-TGR5-cAMP-DIO2 signaling
pathway has been reported to induce the expression of
UCP1 in BAT [29]. Hamada et al. [17] demonstrated
that miglitol increased BA levels in both the feces and
portal blood and tended to increase DIO2 expression.
There was also a positive correlation between the portal
blood BA level and DIO2 gene expression. Based on
these results, the authors speculated that enhancement
of BA by miglitol would increase the DIO2 expression of
BAT, contributing to an increase in UCP1 expression.
Although the energy expenditure of mice (e.g., body
temperature, oxygen consumption) was not measured in
their experiment, their results nonetheless support the
theory that activation of BAT by miglitol contributes to
its anti-obesity effect.
Fig. 1 Orally administered miglitol enters the circulation where it directly enhances the β3-aderenergic signaling of brown adipose tissue (BAT).
Based on Sugimoto et al. [15], Sasaki et al. [18] and Sell et al. [24]. βAR: beta adrenergic signaling; AC: adenylyl cyclase; cAMP: cyclic adenosine
3′,5′-monophosphate; PKA: protein kinase A; p38αMAPK: p38 α-mitogen-activated protein kinase; PGC1α: peroxisome proliferator-activated receptor
gamma coactivator 1α; PPAR: peroxisome proliferator-activated receptor; RXR: retinoid X receptor; PPRE: PPAR response element; CREB: cAMP response
element binding protein; CRE: cAMP response element; HSL: hormone-sensitive lipase; UCP1: uncoupling protein 1; LPL: lipoprotein lipase;
TG: triglyceride; FFA: free fatty acids
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Potential effect of miglitol on white adipocytes
Shrivastava et al. [19] demonstrated that miglitol inhib-
ited the differentiation of 3T3-L1 preadipocytes in a
dose-dependent manner. Based on these results, they hy-
pothesized that miglitol’s anti-obesity effect is attributed
to prevention of the lipid accumulation of WAT. On the
other hand, Sasaki et al. [18] demonstrated that miglitol
did not have an effect on white adipocyte differentiation
markers, even at a millimolar dose. Therefore, whether
or not miglitol has a direct effect on the differentiation
of white preadipocytes requires further investigation.
Collectively, based on the evidence accumulated to
date, it is clear that miglitol has an anti-obesity effect in
rodents as well as humans. Although there are several
hypotheses of the mechanism by which miglitol reduces
obesity, we consider that BAT activation is one of the
crucial mediators of this effect.
Clinical perspectives
The fact that miglitol has been actively used clinically
since 1998 with no severe side effects is noteworthy and
shows its potential for applications in obesity treatment,
although the exact mechanism has not yet been com-
pletely elucidated. Nevertheless, miglitol is associated
with minor side effects such as gastrointestinal symp-
toms [30]. If these side effects are tolerable, miglitol
shows promise as an anti-obesity drug. However, if these
side effects are not acceptable, further investigations into
the mechanism of action of miglitol would be warranted
for the development of a new anti-obesity drug.
At present, the U.S. FDA has approved four anti-
obesity drugs for short-term use (usually considered less
than 12 weeks) and five anti-obesity drugs for long-term
use [2]. The short-term use anti-obesity drugs are norad-
renergic agents (phentermine, diethylpropion, phendi-
metrazine, and benzphetamine), and seem to have an
equivalent or a more slightly enhanced effect on body
weight reduction compared to miglitol [31]. However,
these noradrenergic agents have potential for abuse and
are also contraindicated in patients suffering from ad-
vanced cardiovascular disease, uncontrolled hyperten-
sion, and hyperthyroidism [31]. Because miglitol has no
risk of dependency and is not contraindicated for many
diseases, we believe that it could be more easily tolerated
and administered than these other drugs. The long-term
use anti-obesity drugs are orlistat (a gastrointestinal
lipase inhibitor), lorcaserin (a serotonin 2C receptor
agonist), phentermine/topiramate extended-release (a
sympathomimetic amine with anoretic effect/mechanism
unknown), naltrexone/bupropion (an opioid receptor
antagonist/aminoketone antidepressant), and liraglutide
(a GLP1 receptor agonist). Because the lengths of the
clinical studies conducted thus far to examine miglitol’s
anti-obesity effect are shorter than those conducted for
these five FDA-approved anti-obesity drugs [2, 31], we
cannot directly compare the efficacy for body weight re-
duction between miglitol and these other drugs. The
FDA approved orlistat as an anti-obesity drug in 1999,
and it has been used clinically ever since. Although
orlistat is generally as well tolerated as miglitol, it is con-
traindicated in patients with chronic malabsorption syn-
drome and cholestasis. Furthermore, it is recommended
that patients using orlistat supplement their vitamin in-
take [2]. Therefore, we believe that miglitol would be
easier to use than orlistat for the general population.
Since the other four anti-obesity drugs were approved
only a few years ago [2], sufficient evidence of their
safety is not yet available.
The FDA-approved anti-obesity drugs described above
generally all function via inhibiting energy intake; there-
fore, they fall into the general category of appetite sup-
pressants and lipid absorption inhibitors [2]. Development
of a drug that could enhance energy expenditure would
provide a new category of anti-obesity drug altogether.
Our previous report and that of Sasaki et al. support the
opinion that miglitol activates BAT and induces upregula-
tion of energy expenditure [15, 18]. The work of Hamada
et al. [17] also supports this possibility, although their pro-
posed mechanism is different. Nevertheless, these reports
collectively suggest that miglitol activates BAT, at least in
mice. There has been no clinical investigation of energy
expenditure (i.e., basal metabolism or body temperature)
in response to miglitol administration. Such detailed eval-
uations in future clinical trials could help to verify whether
BAT is involved in miglitol’s anti-obesity effect.
In Japan, a clinical trial of miglitol’s effect on patients
with pediatric type 1 and 2 diabetes is ongoing to evalu-
ate its potential as an anti-diabetic drug. If this trial
demonstrates that miglitol is safe for children, the effi-
cacy of miglitol’s anti-obesity effect on pediatric obesity
would likely be investigated further in the future. Since
aging leads to loss of BAT [21], miglitol’s anti-obesity ef-
fect might be stronger in children as compared with that
observed in adults.
Conclusions
Evidence of miglitol’s anti-obesity effects has been
gradually accumulating in the field of obesity research.
Several clinical and basic research studies have clearly
shown the anti-obesity effect of miglitol in humans and
rodents. Although further research is required to eluci-
date the mechanism of this effect, we can now conclu-
sively state that miglitol shows good potential as a novel
agent for obesity treatment.
Abbreviations
αGI: Alpha-glucosidase inhibitor; BAT: Brown adipose tissue; HOMA-
R: Homeostasis model assessment of insulin resistance; T-Cho: Total
cholesterol; LDL: Low-density lipoprotein; GIP: Glucose-dependent
Sugimoto et al. Nutrition & Metabolism  (2015) 12:51 Page 6 of 7
insulinotropic peptide; GLP1: Glucagon-like peptide 1; UCP1: Uncoupling
protein 1; β3AR: β3-adrenergic receptor; PKA: Protein kinase A;
HSL: Hormone-sensitive lipase; p38αMAPK: p38 α-mitogen-activated protein
kinase; PGC1α: Peroxisome proliferator-activated receptor gamma coactivator
1α; ATF2: Activating transcription factor 2; CREB: cAMP response element
binding protein; DIO2: type 2 iodothyronine deiodinase.
Competing interests
The authors have no competing interests.
Authors’ contributions
SS contributed to the conception and design of the review and was
involved in drafting the manuscript. HN contributed to the conception and
revision of the review. HN, KK and HH provided final approval of the version
to be published. All authors read and approved the final manuscript.
Acknowledgements
We would like to thank Amy Schwartz and the editing team Editage for
English language editing. We also would like to thank Pamela Fujii for
English language editing.
Received: 31 July 2015 Accepted: 25 November 2015
References
1. Dolgin E. A history of drugs on the weight list. Nat Med. 2012;18:843.
2. Patel D. Pharmacotherapy for the management of obesity. Metabolism.
2015;64:1376–85.
3. Kingma PJ, Menheere PP, Sels JP, Nieuwenhuijzen Kruseman AC.
alpha-Glucosidase inhibition by miglitol in NIDDM patients. Diabetes Care.
1992;15:478–83.
4. Shimabukuro M, Higa M, Yamakawa K, Masuzaki H, Sata M. Miglitol, alpha-
glycosidase inhibitor, reduces visceral fat accumulation and cardiovascular
risk factors in subjects with the metabolic syndrome: a randomized
comparable study. Int J Cardiol. 2012;167(5):2108–13.
5. Narita T, Yokoyama H, Yamashita R, Sato T, Hosoba M, Morii T, et al.
Comparisons of the effects of 12-week administration of miglitol and
voglibose on the responses of plasma incretins after a mixed meal in
Japanese type 2 diabetic patients. Diabetes Obes Metab. 2012;14:283–7.
6. Mikada A, Narita T, Yokoyama H, Yamashita R, Horikawa Y, Tsukiyama K,
et al. Effects of miglitol, sitagliptin, and initial combination therapy with
both on plasma incretin responses to a mixed meal and visceral fat in over-
weight Japanese patients with type 2 diabetes. “the MASTER randomized,
controlled trial”. Diabetes Res Clin Pract. 2014;106:538–47.
7. Sugihara H, Nagao M, Harada T, Nakajima Y, Tanimura-Inagaki K, Okajima F,
et al. Comparison of three alpha-glucosidase inhibitors for glycemic control
and bodyweight reduction in Japanese patients with obese type 2 diabetes.
J Diabetes Investig. 2014;5:206–12.
8. Lee A, Patrick P, Wishart J, Horowitz M, Morley JE. The effects of miglitol on
glucagon-like peptide-1 secretion and appetite sensations in obese type 2
diabetics. Diabetes Obes Metab. 2002;4:329–35.
9. Kaku H, Tajiri Y, Yamada K. Anorexigenic effects of miglitol in concert with
the alterations of gut hormone secretion and gastric emptying in healthy
subjects. Horm Metab Res. 2012;44:312–8.
10. Seino Y, Yabe D. Glucose-dependent insulinotropic polypeptide and
glucagon-like peptide-1: incretin actions beyond the pancreas. J Diabetes
Investig. 2013;4:108–30.
11. Miyawaki K, Yamada Y, Ban N, Ihara Y, Tsukiyama K, Zhou H, et al. Inhibition
of gastric inhibitory polypeptide signaling prevents obesity. Nat Med. 2002;
8:738–42.
12. Hayes MR, Kanoski SE, Alhadeff AL, Grill HJ. Comparative effects of the long-
acting GLP-1 receptor ligands, liraglutide and exendin-4, on food intake and
body weight suppression in rats. Obesity (Silver Spring). 2011;19:1342–9.
13. Tang-Christensen M, Larsen PJ, Goke R, Fink-Jensen A, Jessop DS, Moller M,
et al. Central administration of GLP-1-(7–36) amide inhibits food and water
intake in rats. Am J Physiol. 1996;271:R848–56.
14. Turton MD, O’Shea D, Gunn I, Beak SA, Edwards CM, Meeran K, et al. A role
for glucagon-like peptide-1 in the central regulation of feeding. Nature.
1996;379:69–72.
15. Sugimoto S, Nakajima H, Kodo K, Mori J, Matsuo K, Kosaka K, et al. Miglitol
increases energy expenditure by upregulating uncoupling protein 1 of
brown adipose tissue and reduces obesity in dietary-induced obese mice.
Nutr Metab (Lond). 2014;11:14.
16. DeBouno JF, Michaelis Iv OE, Tulp OL. The effects of the intestinal
glucosidase inhibitor BAY M 1099 (miglitol) on glycemic status of obese-
diabetic rats. General Pharmacol Vascular Syst. 1993;24:509–15.
17. Hamada Y, Nagasaki H, Fuchigami M, Furuta S, Seino Y, Nakamura J, et al.
The alpha-glucosidase inhibitor miglitol affects bile acid metabolism and
ameliorates obesity and insulin resistance in diabetic mice. Metabolism.
2013;62:734–42.
18. Sasaki T, Shimpuku M, Kitazumi T, Hiraga H, Nakagawa Y, Shibata H, et al.
Miglitol prevents diet-induced obesity by stimulating brown adipose tissue
and energy expenditure independent of preventing the digestion of
carbohydrates. Endocr J. 2013;60:1117–29.
19. Shrivastava A, Chaturvedi U, Singh SV, Saxena JK, Bhatia G. Lipid lowering
and antioxidant effect of miglitol in triton treated hyperlipidemic and high
fat diet induced obese rats. Lipids. 2013;48(6):597–607.
20. Virtanen KA, Lidell ME, Orava J, Heglind M, Westergren R, Niemi T, et al.
Functional brown adipose tissue in healthy adults. N Engl J Med.
2009;360:1518–25.
21. Cypess AM, Lehman S, Williams G, Tal I, Rodman D, Goldfine AB, et al.
Identification and importance of brown adipose tissue in adult humans.
N Engl J Med. 2009;360:1509–17.
22. van Marken Lichtenbelt WD, Vanhommerig JW, Smulders NM, Drossaerts
JM, Kemerink GJ, Bouvy ND, et al. Cold-activated brown adipose tissue in
healthy men. N Engl J Med. 2009;360:1500–8.
23. Inokuma K, Okamatsu-Ogura Y, Omachi A, Matsushita Y, Kimura K,
Yamashita H, et al. Indispensable role of mitochondrial UCP1 for antiobesity
effect of β3-adrenergic stimulation. Am J Physiol Endocrinol Metab. 2006;
290:E1014–21.
24. Sell H, Deshaies Y, Richard D. The brown adipocyte: update on its metabolic
role. Int J Biochem Cell Biol. 2004;36:2098–104.
25. Fernandez-Marcos PJ, Auwerx J. Regulation of PGC-1α, a nodal regulator of
mitochondrial biogenesis. Am J Clin Nutr. 2011;93:884S–90.
26. Ahr HJ, Boberg M, Brendel E, Krause HP, Steinke W. Pharmacokinetics of
miglitol. Absorption, distribution, metabolism, and excretion following
administration to rats, dogs, and man. Arzneimittelforschung.
1997;47:734–45.
27. Nirogi RV, Kandikere VN, Shukla M, Mudigonda K, Maurya S, Boosi R, et al.
Liquid chromatographic tandem mass spectrometry method for the
quantification of miglitol in human plasma. Arzneimittelforschung. 2006;56:
328–36.
28. Nathan PJ, O’Neill BV, Napolitano A, Bullmore ET. Neuropsychiatric
adverse effects of centrally acting antiobesity drugs. CNS Neurosci Ther.
2011;17:490–505.
29. Watanabe M, Houten SM, Mataki C, Christoffolete MA, Kim BW, Sato H, et al.
Bile acids induce energy expenditure by promoting intracellular thyroid
hormone activation. Nature. 2006;439:484–9.
30. Campbell LK, Baker DE, Campbell RK. Miglitol: assessment of its role in
the treatment of patients with diabetes mellitus. Ann Pharmacother.
2000;34:1291–301.
31. Yanovski SZ, Yanovski JA. Long-term drug treatment for obesity:
a systematic and clinical review. JAMA. 2014;311:74–86.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Sugimoto et al. Nutrition & Metabolism  (2015) 12:51 Page 7 of 7
